Coal tar
This article was originally published in The Tan Sheet
Executive Summary
FDA finds "no adequate basis to change the status of coal tar-containing drug products for the treatment of dandruff, seborrheic dermatitis and psoriasis from OTC to prescription or to require additional warning statements on product labeling," agency says in Feb. 22 response to Occupational Knowledge International's citizen petition seeking Rx-only sales of the ingredient. California Prop 65 litigation had been stayed pending FDA's determination